C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.970
-0.080 (-1.98%)
Nov 21, 2024, 2:34 PM EST - Market open

Company Description

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases.

Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.

The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC.

It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC.

The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

C4 Therapeutics, Inc.
C4 Therapeutics logo
Country United States
Founded 2015
IPO Date Oct 2, 2020
Industry Biotechnology
Sector Healthcare
Employees 145
CEO Andrew Hirsch

Contact Details

Address:
490 Arsenal Way, Suite120
Watertown, Massachusetts 02472
United States
Phone 617 231 0700
Website c4therapeutics.com

Stock Details

Ticker Symbol CCCC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $19.00
CIK Code 0001662579
CUSIP Number 12529R107
ISIN Number US12529R1077
Employer ID 47-5617627
SIC Code 2836

Key Executives

Name Position
Andrew J. Hirsch M.B.A. Chief Executive Officer, President and Director
Dr. Kenneth C. Anderson M.D., Ph.D. Co-Founder, Independent Director and Member of Scientific Advisory Board
Dr. Leonard M. J. Reyno M.D. Chief Medical Officer
Dr. Nathanael S. Gray Ph.D. Co-Founder and Member of Scientific Advisory Board
Kendra Adams Chief Financial Officer and Treasurer
Mark Mossler Chief Accounting Officer
Paige Mahaney Ph.D. Chief Scientific Officer
Courtney Solberg Senior Manager of Investor Relations
Jolie M. Siegel J.D. Chief Legal Officer and Corporate Secretary
Kelly A. Schick Chief People Officer

Latest SEC Filings

Date Type Title
Nov 20, 2024 8-K Current Report
Nov 18, 2024 144 Filing
Nov 15, 2024 424B3 Prospectus
Nov 15, 2024 424B5 Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals